Optimizing Care in HER2+ Breast Cancer: Integrating Fertility Preservation and Advanced Treatment Approaches - Episode 7
Patient-Centered Decisions and Evolving Treatment Landscape for HER2+ Metastatic Breast Cancer
Panelists discuss how treatment decisions in later-line settings should incorporate clinical trials, patient preferences regarding quality of life, medication scheduling, financial considerations, and previous adverse effect experiences, while also addressing special considerations for brain metastases.
Video Player is loading.
Video content above is prompted by the following:
Late-Line Treatment Considerations
Key Themes:
- Clinical trial prioritization
- Recommended as optimal approach when feasible
- Novel antibody-drug conjugates and bispecific antibodies show promise
- Opportunity to access future effective therapies early in development
- Brain metastases management
- T-DXd and tucatinib regimens show efficacy for brain metastases
- Consideration of pan-HER inhibitors like neratinib for central nervous system disease
- Emerging data on targeting HER family receptors (HER1/EGFR, HER3, HER4)
- Patient preferences and quality of life
- Consideration of adverse effect profiles, finances, and treatment scheduling
- Options for oral therapies vs infusions vs subcutaneous injections
- Past adverse effect experiences influence future treatment selections
Notable Insights:
- Dr McCann highlighted: “I think I’m most looking forward to exploring how those triple-positive breast cancer patients who would benefit from an ER-targeted therapy and a HER2-targeted therapy together without a cytotoxic could benefit from all those medications we’re currently using in the hormone receptor–positive, HER2-negative space.”
Dr Vidal concluded: “Clinical trial is no longer a side of the treatment. Clinical trial is an important treatment for every patient you see, regardless; it can be early or late stage.”
Related Content:
